Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study-Reference-Cited by-同舟云学术

Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study

Published:2019-08 Issue: Volume:128 Page:e639-e648
ISSN:1878-8750
Container-title:World Neurosurgery
language:en
Short-container-title:World Neurosurgery

Author:

Higashida Randall T.,Bruder Nicolas,Gupta Rajiv,Guzman Raphael,Hmissi Abdel,Marr Angelina,Mayer Stephan A.,Roux Sébastien,Weidauer Stefan,Aldrich E. François

Funder

Actelion Pharmaceuticals Ltd

University of California

Massachusetts General Hospital

Publisher

Elsevier BV

Subject

Clinical Neurology,Surgery

Reference23 articles.

1. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association;Connolly;Stroke,2012

2. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis;Nieuwkamp;Lancet Neurol,2009

3. Management of aneurysmal subarachnoid hemorrhage;Etminan;Handb Clin Neurol,2017

4. Time course of vasospasm in man;Weir;J Neurosurg,1978

5. Treatment of intracranial vasospasm following subarachnoid hemorrhage;Bauer;Front Neurol,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study;Frontiers in Neurology;2024-06-06

2. Evolving frontiers: endovascular strategies for the treatment of delayed cerebral ischemia;Reviews in the Neurosciences;2024-01-25

3. Current and future strategies for targeting the endothelin pathway in cardiovascular disease;Nature Cardiovascular Research;2023-11-02

4. Fluid balance management with loop diuretics in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A case series;Brain Hemorrhages;2023-10

5. The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage;BMC Neurology;2022-12-20